Telomir Pharmaceuticals, Inc.
Clinical trials sponsored by Telomir Pharmaceuticals, Inc., explained in plain language.
Telomir Pharmaceuticals, Inc.
TELO
NASDAQ
Develops drugs targeting telomerase for cancer and age-related diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill takes on tough breast cancer in first human trial Results expected May 2027 (estimated)